Hlf a

Manufactured by American Type Culture Collection

Sourced in China, United States

The HLF-a is a laboratory equipment product offered by American Type Culture Collection. It is a device designed for the cultivation and maintenance of cell cultures. The core function of the HLF-a is to provide a controlled environment for the growth and propagation of various cell types.

Automatically generated - may contain errors

Lab products found in correlation

Hct116, by American Type Culture Collection (1 mentions) Rpmi 1640 medium, by Corning (1 mentions) Human umbilical vein endothelial cells (huvec), by American Type Culture Collection (1 mentions) Ht 29, by American Type Culture Collection (1 mentions) Hek293t, by American Type Culture Collection (1 mentions) Dulbecco modified eagle medium (dmem), by Corning (1 mentions) Penicillin, by Thermo Fisher Scientific (1 mentions) Streptomycin, by Thermo Fisher Scientific (1 mentions) Hlf a, by Procell (1 mentions) Phorbol 12 myristate 13 acetate, by Merck Group (1 mentions) H1299, by American Type Culture Collection (1 mentions) Hcc827, by American Type Culture Collection (1 mentions) H1650, by American Type Culture Collection (1 mentions) Interleukin 4 (il 4), by MedChemExpress (1 mentions)

2 protocols using hlf a

Cell Culture Conditions for Multiple Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

The human cell lines EJ-1 (CRL-3380, ATCC), HCT 116 (CCL-247, ATCC), MCF7 (HTB-22, ATCC), MDA-MB-231 (HTB-26, ATCC), NCI-H157 (CRL-5802, ATCC), NCI-H292 (CRL-1848, ATCC), NCI-H460 (HTB-177, ATCC), NCI-H661 (HTB-183, ATCC), and T24 (HTB-4, ATCC) were cultured in RPMI-1640 medium (Cellgro, Corning). Human 801-D (200690YJ, KCB, Kunming, China), HEK-293T (CRL-11268, ATCC), HeLa (CCL-2, ATCC), HLF-a (CCL-199, ATCC), HT-29 (HTB-38, ATCC), HUVEC (PCS-100-013, ATCC), LX-2 (337957, BNCC, Beijing, China), SK-MES-1 (HTB-58, ATCC), T98G (CRL-1690, ATCC), and U-87 MG (HTB-14, ATCC) cells were maintained in Dulbecco's modified Eagle medium (DMEM, Cellgro). Human A549 (CCL-185, ATCC), HepG2 (HB-8065, ATCC), K-562 (CCL-243, ATCC), MG-63 (CRL-1427, ATCC), PANC-1 (CRL-1469, ATCC), SaOS2 (HTB-85, ATCC), U2OS (HTB-96, ATCC), and NSC cells were maintained in DMEM: Nutrient Mixture F-12 (Cellgro). The cell lines GBM-18 and GBM-3 were cultured in DMEM (Cellgro).
All culture media was supplemented with 10% fetal bovine serum, 100 unit/mL penicillin and 100 unit/mL streptomycin, and were maintained in a humidified atmosphere containing 5% CO₂ in an incubator at 37 °C.

Wang G., Zhang M., Meng P., Long C., Luo X., Yang X., Wang Y., Zhang Z., Mwangi J., Kamau P.M., Dai Z., Ke Z., Zhang Y., Chen W., Zhao X., Ge F., Lv Q., Rong M., Li D., Jin Y., Sheng X, & Lai R. (2022). Anticarin-β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis. Acta Pharmaceutica Sinica. B, 12(5), 2268-2279.

+ Open protocol

+ Expand

Inducing M2 Macrophages from THP-1 Cells

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Normal human lung cell lines HLF-A was from Procell (Wuhan, China), NSCLC cells HCC827, H1299, H1650, and A549 were from the American Type Culture Collection (ATCC, Maryland, USA), and THP-1 cells were from ATCC.
HLF-A cells were put in minimum essential medium (Thermo Fisher Scientific, Waltham, Massachusetts, USA) containing 1% penicillin, 10% FBS, and streptomycin (Gibco, New York, USA). NSCLC cells HCC827, H1299, and H1650 were put in RPMI-1640 with 10% FBS. THP-1 cells were put in RPMI-1640 with 10% FBS and 0.05 mM 2-mercaptoethanol. A549 cells were grown in ATCC-formulated F-12K (ATCC) containing 10% FBS. All cells were cultivated at 37°C, 5% CO₂.
For macrophage induction, THP-1 cells were differentiated into macrophages by treatment with phorbol 12-myristate 13-acetate (150 nM, Sigma-Aldrich, St Louis, USA) for 1 d [24 (link)]. The cells were developed with 20 ng/mL IL-4 (MedChemExpress, New Jersey, USA) for 48 h to achieve M2 macrophages [13 (link)].

Yang M., Zhou W., Xu M., Han X., Shi Y., Shi M, & Wang Z. (2023). Tumor Suppressor miR-613 Alleviates Non-Small Cell Lung Cancer Cell via Repressing M2 Macrophage Polarization. Journal of Oncology, 2023, 2311231.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!